☆ 4.7 Article

Daily methocinnamox treatment dose-dependently attenuates fentanyl self-administration in rhesus monkeys

NEUROPHARMACOLOGY (2024)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Pharmacology & Pharmacy

Attenuation of the Positive-Reinforcing Effects of Ultra-Potent Fentanyl Analogs, Along with Those of Fentanyl and Heroin, During Daily Treatment with Methocinnamox in Rhesus Monkeys

Lisa R. Gerak et al.

Summary: The opioid crisis will continue without intervention, emphasizing the need for new treatments for opioid use disorder (OUD). Methocinnamox (MCAM), a new m opioid receptor antagonist, shows promise in blocking the effects of fentanyl analogs, but questions remain about its utility. This study investigates MCAM's effectiveness in attenuating the abuse-related effects of carfentanil and 3-methylfentanyl compared to other drugs.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2023)

添加到收藏夹

Review Psychiatry

Fentanyl and Other Opioid Use Disorders: Treatment and Research Needs

Nora D. Volkow et al.

AMERICAN JOURNAL OF PSYCHIATRY (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Effects of 2,5-Dimethoxy-4-Methylamphetamine (DOM) and 2-Piperazin-1-yl-Quinoline (Quipazine) on Fentanyl Versus Food Choice in Rhesus Monkeys

David R. Maguire

Summary: Studies have shown that 5-HT2A receptor agonists do not enhance the reinforcing effects of opioids, suggesting they are unlikely to increase abuse potential.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2023)

添加到收藏夹

Article Psychology, Biological

Behavioral pharmacology of methocinnamox: A potential new treatment for opioid overdose and opioid use disorder

David R. Maguire et al.

Summary: Despite effective medications and efforts, opioid overdose and use disorder remain significant challenges. The emergence of potent opioids like fentanyl has worsened the problem. Behavioral pharmacology research is valuable for understanding drug effects and developing treatments for substance abuse disorders.

JOURNAL OF THE EXPERIMENTAL ANALYSIS OF BEHAVIOR (2023)

添加到收藏夹

Article Substance Abuse

Effects of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and THC/CBD mixtures on fentanyl versus food choice in rhesus monkeys

Lawrence M. Carey et al.

Summary: The study found that THC and CBD, two prominent compounds in cannabis, do not reliably alter the reinforcing effects of opioids.

DRUG AND ALCOHOL DEPENDENCE (2023)

添加到收藏夹

Article Neurosciences

Alkoxy chain length governs the potency of 2-benzylbenzimidazole nitazene' opioids associated with human overdose

Grant C. Glatfelter et al.

Summary: This study examined the effects of nitazene analogues with varying alkoxy chain lengths as compared to reference opioids in vitro and in vivo. The results showed that certain nitazene NSOs are more potent than fentanyl as MOR agonists in mice, raising concerns about the high potential for overdose in humans exposed to these compounds.

PSYCHOPHARMACOLOGY (2023)

添加到收藏夹

Review Medicine, General & Internal

Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission

Keith Humphreys et al.

LANCET (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Effects of Daily Methocinnamox Treatment on Fentanyl Self-Administration in Rhesus Monkeys

David R. Maguire et al.

Summary: Methocinnamox (MCAM), a long-acting mu-opioid receptor antagonist, shows potential as an effective treatment for opioid use disorder. Daily administration of a small dose of MCAM significantly reduces fentanyl self-administration and does not affect cocaine self-administration. The effects of MCAM last for up to 3 days and the treatment shifts the fentanyl dose-effect curve.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2022)

添加到收藏夹

Article Substance Abuse

A synthetic opioid vaccine attenuates fentanyl-vs-food choice in male and female rhesus monkeys

E. Andrew Townsend et al.

Summary: The study evaluated an optimized fentanyl-targeted vaccine in rhesus monkeys and found that vaccination eliminated fentanyl choice in most monkeys, supporting the potential for further clinical evaluation as a candidate Opioid Use Disorder medication.

DRUG AND ALCOHOL DEPENDENCE (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Countermeasures for Preventing and Treating Opioid Overdose

Charles P. France et al.

Summary: The only medication available to prevent and treat opioid overdose is naloxone, approved by the FDA nearly 50 years ago. Due to its limitations, a scientific meeting was convened by NIAID/NIH to explore emerging alternative approaches for treating opioid overdose in the event of weaponization of synthetic opioids. This meeting discussed new approaches such as intranasal nalmefene, methocinnamox, covalent naloxone nanoparticles, serotonin receptor agonists, fentanyl-binding cyclodextrin scaffolds, detoxifying biomimetic nanosponge decoy receptors, and antibody-based strategies.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Methocinnamox Reverses and Prevents Fentanyl-Induced Ventilatory Depression in Rats

Victor M. Jimenez et al.

Summary: This study demonstrates that methocinnamox (MCAM) can reverse and prevent the ventilatory-depressant effects of fentanyl, with a duration of action lasting up to 3 days to at least 2 weeks. This suggests that MCAM might provide an effective treatment option for opioid overdose crisis, particularly from fentanyl and related highly potent analogs.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Long-term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox

Joshua C. Zamora et al.

Summary: Opioid overdose is a major cause of death in the United States, with current treatment mainly relying on the competitive antagonist naloxone. However, the short half-life and surmountable antagonism of naloxone limits its effectiveness. Research suggests that the long-lasting, non-surmountable antagonist methocinnamox (MCAM) may offer an improvement in overdose treatment by targeting mu opioid receptors.

PHARMACOLOGY RESEARCH & PERSPECTIVES (2021)

添加到收藏夹

Article Neurosciences

Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys

David R. Maguire et al.

NEUROPSYCHOPHARMACOLOGY (2020)

添加到收藏夹

Editorial Material Neurosciences

The lasting impact of methocinnamox on opioid self-administration

E. Andrew Townsend

NEUROPSYCHOPHARMACOLOGY (2020)

添加到收藏夹

Article Neurosciences

Methocinnamox (MCAM) antagonizes the behavioral suppressant effects of morphine without impairing delayed matching-to-sample accuracy in rhesus monkeys

Vanessa Minervini et al.

PSYCHOPHARMACOLOGY (2020)

添加到收藏夹

Article Neurosciences

Development of vaccines to treat opioid use disorders and reduce incidence of overdose

Marco Pravetoni et al.

NEUROPHARMACOLOGY (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Reversal and Prevention of the Respiratory-Depressant Effects of Heroin by the Novel μ-Opioid Receptor Antagonist Methocinnamox in Rhesus Monkeys

Lisa R. Gerak et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Long-Lasting Effects of Methocinnamox on Opioid Self-Administration in Rhesus Monkeys

David R. Maguire et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Immunopharmacotherapies for Treating Opioid Use Disorder

Matthew L. Banks et al.

TRENDS IN PHARMACOLOGICAL SCIENCES (2018)

添加到收藏夹

Article Psychology, Biological

Mu/Kappa Opioid Interactions in Rhesus Monkeys: Implications for Analgesia and Abuse Liability

S. Stevens Negus et al.

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY (2008)

添加到收藏夹

Article Neurosciences

Comparison of the antinociceptive effect of acute morphine in female and male Sprague-Dawley rats using the long-lasting mu-antagonist methocinnamox

EM Peckham et al.

BRAIN RESEARCH (2005)

添加到收藏夹

Article Neurosciences

Self-administration of fentanyl, cocaine and ketamine: effects on the pituitary-adrenal axis in rhesus monkeys

JH Broadbear et al.

PSYCHOPHARMACOLOGY (2004)

添加到收藏夹

Article Pharmacology & Pharmacy

Relative reinforcing effects of three opioids with different durations of action

MC Ko et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)

添加到收藏夹

Review Neurosciences

Agonist efficacy, drug dependence, and medications development:: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands

J Bergman et al.

PSYCHOPHARMACOLOGY (2000)

添加到收藏夹

Article Pharmacology & Pharmacy

Antinociceptive and other behavioral effects of the steroid SC17599 are mediated by the μ-opioid receptor

H Houshyar et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.